19th Annual Conference of The Union - North America Region

 

Presentation Slides - February 26, 2015

STOP TB MEETING

Update on Global TB Epidemiology: How Did We Do on the 2006-2015 Global Plan to Stop TB, Where Are We Headed for 2016-35?

Dr. Mario Raviglione, World Health Organization, Geneva, Switzerland

Global MDR-TB Update

Dr. Paul Nunn, London, UK

 

MDR-TB: Linking Diagnosis and Treatment

Dr. Charles Daley, National Jewish Medical and Research Center, Denver, CO, USA

 

Programmatic Technical Assistance in High Burden DR-TB Settings: Targeting Quality of Care with Enhanced Cohort Review

Dr. Lisa Chen, Curry International TB Center, San Francisco, CA, USA

 

Shortened MDR-TB Regimen: Union - Supported Research  

Dr. ID Rusen, The Union, Paris, France (IUATLD)

Oral Abstract Presentation: Multidrug-Resistant Tuberculosis Among Immigrants and Refugees to the United States

Dr. Sasi Jonnalagadda, Centers for Disease Control and Prevention, Atlanta, GA, USA

NURSING-SPONSORED SESSION

Role of Social Determinants of Health on TB among Inuit in Canada  

Ms. Anna Claire Ryan, Inuit Tapiriit Kanatami, Ottawa, ON, Canada

 

TAIMA TB - Community-Driven Studies for TB Prevention and Control in Nunavut

Dr. Gonzalo Alvarez, University of Ottawa, ON, Canada

 

Tipping Points in the TB Experience of Aboriginal Peoples of the Canadian Prairies

Dr. Maria Mayan, University of Alberta, Edmonton, AB, Canada

 

TB and Smoking Cessation Campaign - Multnomah County Experience

Dr. Amy Sullivan, Multnomah County Health Department, Portland, OR, USA

Oral Abstract Presentation: Housing-Related Determinants of Tuberculosis Infection and Disease in a Large Outbreak in an Inuit Community in Nunavik, Quebec

Dr. Faiz Ahmad Khan, McGill International TB Centre, Montreal, QC, Canada

KEYNOTE SPEAKERS

THE BEYOND TB LECTURE – Migrants in Need: Evolving Patterns, Ongoing Challenges

Prof. Catherine Dauvergne, University of British Columbia Law, Vancouver, BC, Canada

THE GEORGE COMSTOCK LECTURE – Why Can’t We Eliminate Tuberculosis?

Dr. Neil Schluger, Columbia University Medical Center, New York, NY, USA

 

Presentation Slides - February 27, 2015

RE-EXAMINING TB CONTROL POLICIES AND CONTROVERSIES

Health Care Worker Screening for LTBI in North America

Dr. Susan Dorman, Johns Hopkins University, Baltimore, MD, USA

 

Value of TB Screening Among Foreign Born Persons: US (California) and Canadian Perspectives

Dr. Pennan Barry, USA California Department of Public Health, Richmond, CA, USA

 

Isolation and Quarantine: Evolving Evidence and Practice—US Public Health Perspective

Dr. Gisela Schecter, UCSF and California Department of Public Health, Richmond, CA, USA

 

Oral Abstract Presentation: Developing a Surveillance Definition for Binational Tuberculosis Cases

Ms. Rachel Yelk-Woodruff, Centers for Disease Control and Prevention, Atlanta, GA, USA

    

TB IN SPECIAL POPULATIONS

 

The Public Health Impact of TB in the Correctional System

Ms. Sarah Bur, Federal Bureau of Prisons, Washington, DC, USA

 

Women and TB: Impact of Gender

Dr. Jane Carter, Brown University, Providence, RI, USA

 

Challenges in Management: Solid Organ Transplantation and Tuberculosis

Dr. Michele I. Morris, University of Miami Miller School of Medicine, Miami, FL, USA

Oral Abstract Presentation: Risk of Adverse Infant Outcomes Associated with Maternal Tuberculosis in a Low Burden Setting

Dr. Sylvia LaCourse, University of Washington, Seattle, WA, USA

 

Presentation Slides - February 28, 2015

TB AND DIABETES

 

Roadblocks on the Path to TB and DM Implementation in New Mexico

Ms. Diana Fortune, New Mexico Department of Health, Santa Fe, NM, USA

 

Implementing TB-DM for your TB Program: Can You? Should You? Will You?

Dr. Richard Brostrom, Department of Health, Honolulu, HI, USA

 

Oral Abstract Presentation: Refugees with Diabetes Mellitus Have Higher Prevalence of Latent Tuberculosis Infection

Dr. Matthew Magee, Georgia State University School of Public Health, Atlanta, GA, USA

TB PHARMACOLOGY

 

Therapeutic Drug Monitoring  for Tuberculosis

Dr. Scott Heysell, University of Virginia School of Medicine, Charlottesville, VA, USA

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes:  A Concept for a Randomized Clinical Trial Before Clinical Implementation

Dr. Randall Reves, Denver Department of Health, Denver, CO, USA

Pharmacokinetics and Doses of Anti-tuberculosis Drugs in Children

Prof. Simon Schaaf, Stellenbosch University, Faculty of Medicine, Cape Town, SA

 

Clinical Trials: Optimal Use of New and Existing Medications

Dr. William J. Burman, Denver Health Hospital, Denver, CO, USA

Oral Abstract Presentation: DM2 is Associated with Severe Adverse Effects in Drug Resistant Tuberculosis

Dr. Marcela Veronica Muñoz-Torrico, National Institute of Respiratory Diseases, Mexico City, Distrito Federal, Mexico

 

 

Privacy Statement & Disclaimer